Related Experiment Video
Updated: Jun 15, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Restenosis rates following vertebral artery origin stenting: does stent type make a difference?
Christopher S Ogilvy1, Xinyu Yang, Sabareesh K Natarajan
1Neurovascular Service, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. cogilvy@partners.org
The Journal of Invasive Cardiology
|March 4, 2010
Summary
Drug-eluting stents (DES) may reduce restenosis in vertebral artery (VA) origin stenosis compared to non-drug-eluting stents (NDES). Further randomized trials are needed to confirm these findings for VA stenosis treatment.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Vascular Surgery
Background:
- Vertebral artery (VA) origin stenosis poses a risk for stroke.
- Treatment options include stenting with drug-eluting stents (DES) or non-drug-eluting stents (NDES).
- Comparative data on DES versus NDES for VA stenosis is limited.
Purpose of the Study:
- To compare the efficacy and safety of DES versus NDES in treating VA origin stenosis.
- To review existing literature on stenting for VA stenosis.
Main Methods:
- Retrospective review of a prospectively collected database of patients undergoing stenting for VA origin stenosis.
- Inclusion criteria: symptomatic >60% stenosis or asymptomatic >70% stenosis with risk factors.
- Data collected: demographics, comorbidities, procedural details, clinical and radiological outcomes.
Main Results:
- Thirty-five patients received NDES and 15 received DES; technical success was 100% with no procedural complications.
- Symptom resolution: 96.8% with NDES, 91.7% with DES.
- In-stent restenosis: 38% in NDES group vs. 17% in DES group. No DES patients required re-angioplasty, while 7 NDES patients did.
Conclusions:
- Drug-eluting stents (DES) may offer a reduced incidence of restenosis compared to non-drug-eluting stents (NDES) in vertebral artery origin stenosis.
- The findings suggest DES may be a superior option for managing VA stenosis.
- Prospective, randomized, multicenter trials are necessary to validate these results.